Advertisement

Annals of Surgical Oncology

, Volume 16, Issue 10, pp 2926–2935 | Cite as

Allelic Imbalance at p53 and Microsatellite Instability Are Predictive Markers for Resistance to Chemotherapy in Gastric Carcinoma

  • Masakazu Yashiro
  • Toru Inoue
  • Nobuaki Nishioka
  • Tasuku Matsuoka
  • C. Richard Boland
  • Kosei Hirakawa
Translational Research and Biomarkers

Abstract

Background

Combined treatment with 5-fluorouracil and cisplatin (FP chemotherapy) is an effective neoadjuvant regimen for gastric carcinoma. However, it is ineffective in half of all patients. This study tests the hypothesis that genetic markers might identify those patients with gastric cancer who would respond to neoadjuvant FP chemotherapy.

Materials and Methods

A total of 23 patients with gastric carcinoma were treated with neoadjuvant chemotherapy. Pretreatment biopsy specimens before neoadjuvant chemotherapy were obtained from 15 of 23 patients, and resected tumors were obtained from all 23. Genetic studies were performed to detect allelic imbalance (AI), microsatellite instability (MSI), and K-ras mutation.

Results

A clinical response was observed in 13 of 23 patients. Kaplan–Meier survival curve showed that clinical responder group had a significantly higher likelihood of overall survival (P = 0.0165), compared with nonresponder group. In 23 resection specimens, 10 of 23 tumors presented AI at the p53 locus and/or MSI; 8 of the 10 tumors were nonresponders, while 12 of 13 tumors without p53 AI or MSI were responders (P = 0.0007). In 15 pretreatment biopsy specimens, 8 tumors had p53 AI and/or MSI; 7 of the 8 tumors were nonresponders, while 6 of 7 tumors without p53 AI or MSI were responders to preoperative chemotherapy (P = 0.008). Tumors with AI at the p53 locus and/or MSI were significantly more resistant to neoadjuvant chemotherapy. No relationship was found between K-ras mutations and responses.

Conclusions

Analysis for p53 AI and MSI might represent a clinically useful approach to predicting the response to neoadjuvant FP chemotherapy in gastric carcinoma.

Keywords

Gastric Cancer Gastric Carcinoma Preoperative Chemotherapy Allelic Imbalance Pretreatment Biopsy Specimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This study is partially founded by Grants in Aid for Scientific Research (No. 18591475, 20591073, and 18390369) from the Ministry of Education, Science, Sports, Culture, and Technology of Japan, by a JSGE Grant in Aid for Scientific Research, by a Grant in Aid for Kobayashi Foundation for Innovative Cancer Chemotherapy, by a Grant in Aid for the Sagawa Foundation for Cancer Research, by a Grant in Aid for the Osaka Medical Research Foundation for Incurable Diseases, and by NIH grant R01 CA75821 to CRB. The authors have no conflicts of interest to disclose.

Supplementary material

10434_2009_590_MOESM1_ESM.doc (36 kb)
Supplementary material 1 (DOC 36 kb)

References

  1. 1.
    D’Ugo D, Persiani R, Rausei S, Biondi A, Vigorita V, Boccia S, et al. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol. 2006;32:1105–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007;13:168–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2007;25:2580–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, et al. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer. 1997;80:1–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17:1404–11.CrossRefPubMedGoogle Scholar
  7. 7.
    De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, et al. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol. 2007;18 Suppl 6:vi120–3.CrossRefPubMedGoogle Scholar
  8. 8.
    Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest. 2006;24:235–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Hofler H, Langer R, Ott K, Keller G. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Recent Results Cancer Res. 2007;176:33–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.CrossRefPubMedGoogle Scholar
  11. 11.
    Hamilton JP, Meltzer SJ. A review of the genomics of gastric cancer. Clin Gastroenterol Hepatol. 2006;4:416–25.CrossRefPubMedGoogle Scholar
  12. 12.
    Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ. Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. Gastroenterology. 1994;106:1584–8.PubMedGoogle Scholar
  13. 13.
    Houghton JA, Ebanks R, Harwood FG, Tillman DM. Inhibition of apoptosis after thymineless stress is conferred by oncogenic K-Ras in colon carcinoma cells. Clin Cancer Res. 1998;4:2841–8.PubMedGoogle Scholar
  14. 14.
    Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 2006;119:2030–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003;63:1608–14.PubMedGoogle Scholar
  16. 16.
    Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127–38.CrossRefPubMedGoogle Scholar
  17. 17.
    Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 1999;117:123–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Zoli W, Ricotti L, Lenzi L, Roncuzzi L, Zini N, Amadori D, et al. Molecular genetics and in vitro sensitivity of a new human cell line, KKP, from a gastric adenocarcinoma. Cancer Genet Cytogenet. 1998;105:43–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Ott K, Vogelsang H, Mueller J, Becker K, Müller M, Fink U, et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res. 2003;9:2307–15.PubMedGoogle Scholar
  20. 20.
    Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res. 2000;6:4782–88.PubMedGoogle Scholar
  21. 21.
    Japanese Gastric Cancer A. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1998;1:10–24.CrossRefGoogle Scholar
  22. 22.
    Kim MA, Lee HS, Yang HK, Kim WH. Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer 2005;103:1439–46.CrossRefPubMedGoogle Scholar
  23. 23.
    Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMedGoogle Scholar
  24. 24.
    Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57.PubMedGoogle Scholar
  25. 25.
    Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res. 2001;61:2676–83.PubMedGoogle Scholar
  26. 26.
    Inada T, Ogata Y, Kubota T, Tomikawa M, Yamamoto S, Andoh J, et al. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer. Anticancer Res. 2000;20:2457–62.PubMedGoogle Scholar
  27. 27.
    Ozguroglu M, Demir G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 1999;86:547–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 1998;83:1917–22.CrossRefPubMedGoogle Scholar
  29. 29.
    Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol. 2000;18:1465–73.PubMedGoogle Scholar
  30. 30.
    Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics. 1999;58:310–2.CrossRefPubMedGoogle Scholar
  31. 31.
    Ming SC. Cellular and molecular pathology of gastric carcinoma and precursor lesions: A critical review. Gastric Cancer. 1998;1:31–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 1990;48:381–95.CrossRefPubMedGoogle Scholar
  33. 33.
    Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996;56:689–93.PubMedGoogle Scholar
  34. 34.
    Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74:957–67.CrossRefPubMedGoogle Scholar
  35. 35.
    Bursch W, Kleine L, Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol. 1990;68:1071–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 1996;56:3087–90.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2009

Authors and Affiliations

  • Masakazu Yashiro
    • 1
    • 2
  • Toru Inoue
    • 1
  • Nobuaki Nishioka
    • 1
  • Tasuku Matsuoka
    • 1
  • C. Richard Boland
    • 3
  • Kosei Hirakawa
    • 1
  1. 1.Department of Surgical OncologyOsaka City University Graduate School of MedicineOsakaJapan
  2. 2.Oncology Institute of Geriatrics and Medical ScienceOsaka City University Graduate School of MedicineOsakaJapan
  3. 3.Division of GastroenterologyBaylor University Medical CenterDallasTX

Personalised recommendations